However, composite hospitalizations 11 , 25 , 27 , 35 due to cardiovascular events, heart failure, or heart failure exacerbations were not reduced by tafamidis compared with placebo, although there was a trend toward significance ( Figure 5 ).
← all excerpts
Effect of Tafamidis on Clinical and Functional Parameters in Transthyretin Amyloid Cardiomyopathy.
1
—
—